# Nucleus Genomics

> Nucleus Genomics is a New York-based consumer genomics company that sells a $399 at-home, clinical-grade whole-genome sequencing kit and a software platform that turns a person's full DNA sequence into readable reports on disease risk, carrier status, traits, and longevity. Founded in 2021 by Thiel Fellow Kian Sadeghi, Nucleus pairs whole-genome data with polygenic risk scores and lifestyle inputs to estimate risk for common, complex conditions. In 2025 it expanded into reproductive products - carrier screening, partner DNA alignment, and a controversial embryo-ranking tool, Nucleus Embryo - that put the company at the center of a public debate over the science and ethics of genetic selection.

- **Founded:** 2021
- **Headquarters:** New York, United States
- **Founders:** Kian Sadeghi (Founder & CEO)
- **Team size:** ~41 employees
- **Products:** Nucleus (Whole-Genome Sequencing Kit), Nucleus Platform & Membership, Health & Disease Reports, Carrier Screening & DNA Alignment, Nucleus Embryo / IVF+
- **Notable:** Brought clinical-grade whole-genome sequencing to consumers at a ~$399 price point., Raised roughly $32M total, including a $14M Series A in January 2025., Backed by high-profile investors including Peter Thiel, Alexis Ohanian, and Founders Fund.

## Products & services

- **Nucleus (Whole-Genome Sequencing Kit)** — An at-home, clinical-grade 30x whole-genome sequencing kit priced around $399 that reads nearly 100% of a customer's genome versus the ~0.02% read by typical at-home DNA chips.
- **Nucleus Platform & Membership** — A software platform that turns genome data into reports on disease risk, traits, and ancestry, using polygenic risk scores combined with lifestyle and environmental inputs. A ~$39/year membership unlocks new reports over time.
- **Health & Disease Reports** — Risk reports for common, complex conditions plus detection of rare, novel, and large structural variants enabled by full genome sequencing.
- **Carrier Screening & DNA Alignment** — Carrier screening and a couples 'DNA alignment' feature that estimates the risk of passing on roughly 900 inherited conditions to children.
- **Nucleus Embryo / IVF+** — A software product that lets prospective parents analyze and rank IVF embryos across disease risk and traits, offered with partner fertility clinics. The product has drawn significant scientific and ethical criticism.
- **Nucleus Longevity & Nucleus Traits** — Reports estimating genetic predisposition for traits and the likelihood of living past age 80.

## Achievements

- Brought clinical-grade whole-genome sequencing to consumers at a ~$399 price point.
- Raised roughly $32M total, including a $14M Series A in January 2025.
- Backed by high-profile investors including Peter Thiel, Alexis Ohanian, and Founders Fund.
- Built a platform that sequences nearly 100% of the genome and detects rare and structural variants.
- Expanded into reproductive health and international markets within a few years of launch.

## Latest updates

- **2025-01** — Closed a $14M Series A, bringing total funding to roughly $32M.
- **2025-05** — Launched its IVF embryo analysis product, Nucleus Embryo.
- **2025-08** — Beverly Hills Fertility became the first clinic to join the Nucleus IVF network.
- **2025-11** — 'Have your best baby' subway ad campaign sparked widespread scientific and ethical debate.

## Links

- Website: https://mynucleus.com
- LinkedIn: https://www.linkedin.com/company/nucleusgenomics
- Twitter/X: https://twitter.com/nucleusgenomics
- Instagram: https://www.instagram.com/nucleusgenomics/

---

Profile page: https://yespress.io/nucleus-genomics
Published by YesPress — https://yespress.io
Last updated: 2026-06-13